Baxter International (BAX) Receiving Somewhat Positive Press Coverage, Report Finds
News headlines about Baxter International (NYSE:BAX) have trended somewhat positive on Friday, Accern reports. Accern scores the sentiment of press coverage by analyzing more than 20 million news and blog sources in real time. Accern ranks coverage of publicly-traded companies on a scale of negative one to one, with scores nearest to one being the most favorable. Baxter International earned a news sentiment score of 0.07 on Accern’s scale. Accern also assigned news coverage about the medical instruments supplier an impact score of 46.1888300010104 out of 100, meaning that recent press coverage is somewhat unlikely to have an impact on the stock’s share price in the near term.
These are some of the media stories that may have effected Accern’s scoring:
- Carole J. Shapazian Sells 4,020 Shares of Baxter International Inc. (BAX) Stock (americanbankingnews.com)
- Top Trends on Fluid Management Systems Market to 2021 “Company Profile, Competitive Landscape and Key Development” (medgadget.com)
- Momentum Stock in Focus: Baxter International Inc. (BAX) (vothemes.com)
- United States’ nephrology and urology devices market outlook to 2023 examined in new market research report (whatech.com)
- Technical Snapshots for These Medical Supplies Stocks — Dextera … – Markets Insider (markets.businessinsider.com)
A number of brokerages have recently issued reports on BAX. Citigroup Inc. began coverage on shares of Baxter International in a research report on Thursday, August 17th. They set a “neutral” rating and a $63.00 target price on the stock. BidaskClub upgraded shares of Baxter International from a “buy” rating to a “strong-buy” rating in a research report on Monday, August 14th. Zacks Investment Research lowered shares of Baxter International from a “buy” rating to a “hold” rating in a research report on Tuesday, August 1st. UBS AG lifted their price objective on shares of Baxter International from $57.00 to $62.00 and gave the company a “neutral” rating in a research report on Friday, July 28th. Finally, Leerink Swann reiterated an “outperform” rating and issued a $75.00 price objective (up from $67.00) on shares of Baxter International in a research report on Thursday, July 27th. One investment analyst has rated the stock with a sell rating, six have assigned a hold rating, six have assigned a buy rating and two have issued a strong buy rating to the company. The company currently has a consensus rating of “Buy” and a consensus price target of $65.15.
Baxter International (BAX) remained flat at $61.51 during midday trading on Friday. 2,389,377 shares of the company’s stock were exchanged. The firm has a market capitalization of $33.51 billion, a P/E ratio of 37.32 and a beta of 0.66. Baxter International has a 12-month low of $43.13 and a 12-month high of $63.14. The company has a 50-day moving average of $61.03 and a 200-day moving average of $56.34.
Baxter International (NYSE:BAX) last released its earnings results on Wednesday, July 26th. The medical instruments supplier reported $0.63 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of $0.57 by $0.06. Baxter International had a return on equity of 14.82% and a net margin of 8.85%. The company had revenue of $2.61 billion during the quarter, compared to analysts’ expectations of $2.59 billion. During the same period last year, the firm earned $0.46 EPS. The business’s revenue for the quarter was up .8% on a year-over-year basis. Equities analysts predict that Baxter International will post $2.39 EPS for the current year.
The firm also recently announced a quarterly dividend, which will be paid on Monday, October 2nd. Shareholders of record on Friday, September 1st will be issued a dividend of $0.16 per share. The ex-dividend date of this dividend is Wednesday, August 30th. This represents a $0.64 annualized dividend and a yield of 1.04%. Baxter International’s dividend payout ratio is presently 38.79%.
In related news, SVP Giuseppe Accogli sold 12,670 shares of the company’s stock in a transaction dated Thursday, August 17th. The stock was sold at an average price of $60.96, for a total transaction of $772,363.20. Following the sale, the senior vice president now owns 33,286 shares in the company, valued at $2,029,114.56. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director Carole J. Shapazian sold 4,020 shares of the company’s stock in a transaction dated Thursday, August 24th. The stock was sold at an average price of $61.61, for a total value of $247,672.20. Following the sale, the director now owns 13,868 shares in the company, valued at approximately $854,407.48. The disclosure for this sale can be found here. Insiders own 0.05% of the company’s stock.
About Baxter International
Baxter International Inc, through its subsidiaries, provides renal and hospital products. The Company operates through two segments: Hospital Products and Renal. Its Hospital Products business manufactures sterile intravenous (IV) solutions and administration sets, premixed drugs and drug-reconstitution systems, pre-filled vials and syringes for injectable drugs, IV nutrition products, parenteral nutrition therapies, infusion pumps, inhalation anesthetics and biosurgery products.
Receive News & Stock Ratings for Baxter International Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Baxter International Inc. and related stocks with our FREE daily email newsletter.